These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39094121)

  • 1. Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
    Mansilla-Polo M; Martín-Torregrosa D; Martínez-Cozar V; Arnao-Herraiz M; Botella-Estrada R
    J Dtsch Dermatol Ges; 2024 Aug; ():. PubMed ID: 39094121
    [No Abstract]   [Full Text] [Related]  

  • 2. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab.
    Lery M; Perrot A; Ortiz-Brugués A; Vigarios E; Anghel D; Bories P; Sibaud V
    J Am Acad Dermatol; 2024 Feb; 90(2):376-377. PubMed ID: 37742842
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
    Laheij AMGA; van de Donk NWCJ
    Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
    Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
    N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma.
    Shaver J; Horton D; Halford Z
    Ann Pharmacother; 2024 Aug; ():10600280241271192. PubMed ID: 39192558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma.
    Jeong J; Park J; Young Mo G; Shin J; Cho Y
    J Mol Biol; 2024 Oct; 436(20):168748. PubMed ID: 39181182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.
    Pan D; Richter J
    Curr Hematol Malig Rep; 2024 Aug; ():. PubMed ID: 39145912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
    Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
    Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma.
    Narayan N; Williams B; Lipe B; De Benedetto A
    JAAD Case Rep; 2023 Jan; 31():66-68. PubMed ID: 36505036
    [No Abstract]   [Full Text] [Related]  

  • 10. Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma.
    Heini AD; Bacher VU; Akhoundova D; Seipel K; Pabst T
    Acta Haematol; 2024 Mar; ():. PubMed ID: 38447541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
    Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
    Chari A; Askari E; Caers J; Costa LJ; Hilder BW; Krishnan A; Mateos MV; Minnema MC; Oriol A; Pillarisetti K; van de Donk NWCJ; Rodríguez-Otero P
    Future Oncol; 2023 Sep; 19(27):1823-1840. PubMed ID: 37492991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
    Shrestha A; Alzubi M; Alrawabdeh J; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Al Hadidi S
    EJHaem; 2024 Jun; 5(3):554-559. PubMed ID: 38895072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talquetamab: First Approval.
    Keam SJ
    Drugs; 2023 Oct; 83(15):1439-1445. PubMed ID: 37792138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MonumenTAL Results for Talquetamab in Myeloma.
    Cancer Discov; 2023 Feb; 13(2):250-251. PubMed ID: 36508587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
    Einsele H; Moreau P; Bahlis N; Bhutani M; Vincent L; Karlin L; Perrot A; Goldschmidt H; van de Donk NWCJ; Ocio EM; Martinez-Lopez J; Rodríguez-Otero P; Dytfeld D; Diels J; Strulev V; Haddad I; Renaud T; Ammann E; Cabrieto J; Perualila N; Gan R; Zhang Y; Parekh T; Albrecht C; Weisel K; Mateos MV
    Adv Ther; 2024 Apr; 41(4):1576-1593. PubMed ID: 38402374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab.
    Naqvi S; Shrestha A; Alzubi M; Alrawabdeh J; Thanendrarajan S; Zangari M; van Rhee F; Schinke C; Al Hadidi S
    EJHaem; 2024 Aug; 5(4):789-792. PubMed ID: 39157593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.